Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash & Equivalents: 2016-2023

Historic Cash & Equivalents for Solid Biosciences (SLDB) over the last 8 years, with Dec 2023 value amounting to $74.0 million.

  • Solid Biosciences' Cash & Equivalents rose 31.32% to $64.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $64.4 million, marking a year-over-year increase of 31.32%. This contributed to the annual value of $74.0 million for FY2023, which is 52.37% down from last year.
  • Latest data reveals that Solid Biosciences reported Cash & Equivalents of $74.0 million as of FY2023, which was down 52.37% from $155.4 million recorded in FY2022.
  • In the past 5 years, Solid Biosciences' Cash & Equivalents registered a high of $155.4 million during FY2022, and its lowest value of $74.0 million during FY2023.
  • Its 3-year average for Cash & Equivalents is $116.2 million, with a median of $119.1 million in 2021.
  • As far as peak fluctuations go, Solid Biosciences' Cash & Equivalents soared by 103.50% in 2020, and later plummeted by 52.37% in 2023.
  • Yearly analysis of 5 years shows Solid Biosciences' Cash & Equivalents stood at $76.0 million in 2019, then soared by 103.50% to $154.7 million in 2020, then dropped by 23.01% to $119.1 million in 2021, then soared by 30.43% to $155.4 million in 2022, then slumped by 52.37% to $74.0 million in 2023.